Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2013American Journal of Nephrology

Ac-SDKP administration significantly reduced renal fibrosis in diabetic rats, and its addition to ramipril further reduced renal fibrosis compared to ramipril alone.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does Ac-SDKP reduce renal fibrosis in a diabetic rat model when used alone or added to an ACE inhibitor?

Population

38 Sprague-Dawley rats (28 with streptozotocin-induced diabetes, 10 non-diabetic controls)

Comparison

N-acetyl-seryl-aspartyl-lysyl-proline 1… vs Saline solution via osmotic minipumps or…

Design

Preclinical

Follow-up

8 weeks

Authors

GCGiovanna CastoldiCGCira Di GioiaCBC. Bombardi

Discussion

Loading...

Member takes

Overview

Ac-SDKP may offer additive antifibrotic benefit with ACE inhibition in diabetic nephropathy; hypothesis-generating in rats, requiring clinical validation.

Structured PICO

Does Ac-SDKP reduce renal fibrosis in a diabetic rat model when used alone or added to an ACE inhibitor?

P
Population
38 Sprague-Dawley rats (28 with streptozotocin-induced diabetes, 10 non-diabetic controls)
I
Intervention
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) 1 mg/kg/day administered by osmotic minipumps for 8 weeks, either alone or added to ramipril (3 mg/kg/day)
C
Comparator
Saline solution via osmotic minipumps (sham treatment) or ramipril alone
O
Outcome
Renal fibrosissurrogate

Ac-SDKP reduces renal fibrosis in a diabetic rat model and provides additive antifibrotic effects when combined with ACE inhibition.

Cite This Study

Castoldi et al. (2013) studied this question.

synapsesocial.com/papers/6a8936c5a7eee2293bcaf62ehttps://doi.org/10.1159/000346116
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats2009 · 33 citations
  2. 2Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen2016 · 42 citations
  3. 3<i>N</i> -Acetyl-Seryl-Aspartyl-Lysyl-Proline Attenuates Renal Injury and Dysfunction in Hypertensive Rats With Reduced Renal Mass2009 · 47 citations
  4. 4Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension2004 · 97 citations
  5. 5Antifibrotic Effects of<i>N</i>-Acetyl-Seryl-Aspartyl-Lysyl-Proline on the Heart and Kidney in Aldosterone-Salt Hypertensive Rats2001 · 95 citations